Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.

A QSAR based predictive model of hERG activity in terms of 'global descriptors' has been developed and evaluated. The QSAR was developed by training 77 compounds covering a wide range of activities and was validated based on an external 'test set' of 80 compounds using neural network method. Statistical parameters and examination of enrichment factor indicated the effectiveness of the present model. Randomization test demonstrated the robustness of the model and cross-validation test further validated the QSAR. Domain of applicability test indicated to the high degree of reliability of the predicted results. Satisfactory performance in classifying compounds into 'active' and 'inactive' groups was also obtained. The cases where the QSAR failed, the possible sources of errors have been discussed.

[1]  A. Bianucci,et al.  Prediction of hERG potassium channel affinity by the CODESSA approach. , 2006, Bioorganic & medicinal chemistry.

[2]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[3]  Bo Nordén,et al.  Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships. , 2008, Journal of medicinal chemistry.

[4]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[5]  Laurene V. Fausett,et al.  Fundamentals Of Neural Networks , 1993 .

[6]  Tudor I. Oprea,et al.  hERG classification model based on a combination of support vector machine method and GRIND descriptors. , 2008, Molecular pharmaceutics.

[7]  Gajendra P. S. Raghava,et al.  AlgPred: prediction of allergenic proteins and mapping of IgE epitopes , 2006, Nucleic Acids Res..

[8]  G. Keserü.  Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.

[9]  Brian B. Goldman,et al.  A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.

[10]  Richard A. Friesner,et al.  Comparative Performance of Several Flexible Docking Programs and Scoring Functions: Enrichment Studies for a Diverse Set of Pharmaceutically Relevant Targets , 2007, J. Chem. Inf. Model..

[11]  C. Valdivia,et al.  Drug‐induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine , 2006, British journal of pharmacology.

[12]  Gisbert Schneider,et al.  A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.

[13]  Kevin N. Gurney,et al.  An introduction to neural networks , 2018 .

[14]  George Kollias,et al.  A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. , 2009, European journal of medicinal chemistry.

[15]  J. Li,et al.  A two-state homology model of the hERG K+ channel: application to ligand binding. , 2005, Bioorganic & medicinal chemistry letters.

[16]  Rachid Darnag,et al.  Support vector machines: development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives. , 2010, European journal of medicinal chemistry.

[17]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. S. Lee,et al.  Ionic mechanism of ibutilide in human atrium: evidence for a drug-induced Na+ current through a nifedipine inhibited inward channel. , 1998, The Journal of pharmacology and experimental therapeutics.

[19]  A. Hoes,et al.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.

[20]  C. Michael Stein,et al.  Oral erythromycin and the risk of sudden death from cardiac causes , 2004 .

[21]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[22]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[23]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[24]  Pierre Baldi,et al.  Assessing the accuracy of prediction algorithms for classification: an overview , 2000, Bioinform..

[25]  Rosella Ombrato,et al.  General and independent approaches to predict HERG affinity values , 2004 .

[26]  R. Friesner,et al.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.

[27]  Gabriele Cruciani,et al.  Predictive models for hERG potassium channel blockers. , 2005, Bioorganic & medicinal chemistry letters.

[28]  R. Lazzara,et al.  Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride , 2002, Journal of cardiovascular pharmacology and therapeutics.

[29]  T. Nishikawa,et al.  A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[30]  Igor V. Tetko,et al.  Critical Assessment of QSAR Models of Environmental Toxicity against Tetrahymena pyriformis: Focusing on Applicability Domain and Overfitting by Variable Selection , 2008, J. Chem. Inf. Model..

[31]  Z. Rankovic,et al.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.

[32]  M. Killeen.  Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry. , 2009, Drug discovery today.

[33]  G. Ecker,et al.  A binary QSAR model for classification of hERG potassium channel blockers. , 2008, Bioorganic & medicinal chemistry.

[34]  Robert Pearlstein,et al.  Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. , 2003, Journal of medicinal chemistry.

[35]  Boris Mirkin,et al.  A Measure of Domain of Applicability for QSAR Modelling Based on Intelligent K-Means Clustering , 2007 .

[36]  J. Tamargo,et al.  Pharmacology of Cardiac Potassium Channels , 2003 .

[37]  Dimitris K Agrafiotis,et al.  A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set , 2006, Chemical biology & drug design.

[38]  Alex M Aronov,et al.  Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.

[39]  Matthew Clark,et al.  Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..